vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Essex Property Trust（ESS）财务数据对比。点击上方公司名可切换其他公司
Essex Property Trust的季度营收约是BIOCRYST PHARMACEUTICALS INC的3.1倍（$479.6M vs $156.4M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs 5.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 6.0%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
BCRX vs ESS — 直观对比
营收规模更大
ESS
是对方的3.1倍
$156.4M
营收增速更快
BCRX
高出1.9%
5.5%
两年增速更快
BCRX
近两年复合增速
6.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $479.6M |
| 净利润 | — | $85.7M |
| 毛利率 | — | 70.0% |
| 营业利润率 | 13.6% | 31.7% |
| 净利率 | — | 17.9% |
| 营收同比 | 7.5% | 5.5% |
| 净利润同比 | — | -71.6% |
| 每股收益（稀释后） | $0.00 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXESS
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $479.6M | ||
| Q3 25 | $159.4M | $473.3M | ||
| Q2 25 | $163.4M | $469.8M | ||
| Q1 25 | $145.5M | $464.6M | ||
| Q4 24 | $131.5M | $454.5M | ||
| Q3 24 | $117.1M | $450.7M | ||
| Q2 24 | $109.3M | $442.4M |
净利润BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $85.7M | ||
| Q3 25 | $12.9M | $172.7M | ||
| Q2 25 | $5.1M | $231.5M | ||
| Q1 25 | $32.0K | $212.8M | ||
| Q4 24 | $-26.8M | $301.7M | ||
| Q3 24 | $-14.0M | $125.5M | ||
| Q2 24 | $-12.7M | $99.0M |
毛利率BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 70.0% | ||
| Q3 25 | 98.6% | 69.2% | ||
| Q2 25 | 98.3% | 70.7% | ||
| Q1 25 | 96.9% | 69.6% | ||
| Q4 24 | 95.4% | 70.0% | ||
| Q3 24 | 97.3% | 69.5% | ||
| Q2 24 | 98.4% | 70.8% |
营业利润率BCRXESS
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 31.7% | ||
| Q3 25 | 18.6% | 44.5% | ||
| Q2 25 | 18.2% | 59.5% | ||
| Q1 25 | 14.6% | 55.3% | ||
| Q4 24 | -3.4% | 67.0% | ||
| Q3 24 | 6.6% | 28.6% | ||
| Q2 24 | 8.0% | 31.1% |
净利率BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 17.9% | ||
| Q3 25 | 8.1% | 36.5% | ||
| Q2 25 | 3.1% | 49.3% | ||
| Q1 25 | 0.0% | 45.8% | ||
| Q4 24 | -20.4% | 66.4% | ||
| Q3 24 | -12.0% | 27.8% | ||
| Q2 24 | -11.6% | 22.4% |
每股收益（稀释后）BCRXESS
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $1.24 | ||
| Q3 25 | $0.06 | $2.56 | ||
| Q2 25 | $0.02 | $3.44 | ||
| Q1 25 | $0.00 | $3.16 | ||
| Q4 24 | $-0.13 | $4.00 | ||
| Q3 24 | $-0.07 | $1.84 | ||
| Q2 24 | $-0.06 | $1.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $76.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $5.5B |
| 总资产 | $465.1M | $13.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXESS
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $76.2M | ||
| Q3 25 | $212.9M | $66.0M | ||
| Q2 25 | $260.0M | $58.7M | ||
| Q1 25 | $295.1M | $98.7M | ||
| Q4 24 | $320.9M | $66.8M | ||
| Q3 24 | $96.8M | $71.3M | ||
| Q2 24 | $78.4M | $55.2M |
总债务BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.2B |
股东权益BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $5.5B | ||
| Q3 25 | $-387.9M | $5.6B | ||
| Q2 25 | $-421.6M | $5.6B | ||
| Q1 25 | $-451.9M | $5.6B | ||
| Q4 24 | $-475.9M | $5.5B | ||
| Q3 24 | $-468.6M | $5.4B | ||
| Q2 24 | $-475.6M | $5.5B |
总资产BCRXESS
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $13.2B | ||
| Q3 25 | $446.4M | $13.2B | ||
| Q2 25 | $457.2M | $13.2B | ||
| Q1 25 | $480.0M | $13.2B | ||
| Q4 24 | $490.4M | $12.9B | ||
| Q3 24 | $491.3M | $12.6B | ||
| Q2 24 | $472.4M | $12.5B |
负债/权益比BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.22× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $1.1B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 12.53× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $1.1B | ||
| Q3 25 | $41.6M | $342.6M | ||
| Q2 25 | $41.3M | $216.1M | ||
| Q1 25 | $-27.5M | $281.5M | ||
| Q4 24 | $-5.2M | $1.1B | ||
| Q3 24 | $8.2M | $316.2M | ||
| Q2 24 | $-1.4M | $218.9M |
自由现金流BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — |
自由现金流率BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — |
资本支出强度BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
现金转化率BCRXESS
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 12.53× | ||
| Q3 25 | 3.23× | 1.98× | ||
| Q2 25 | 8.12× | 0.93× | ||
| Q1 25 | -859.91× | 1.32× | ||
| Q4 24 | — | 3.54× | ||
| Q3 24 | — | 2.52× | ||
| Q2 24 | — | 2.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
ESS
暂无分部数据
